Skip to main content

Opdyta 100 mg | Nivolumab | Blueberry pharmaceuticals

OPDYTA 100MG

Opdyta 100mg belongs to a group of cancer drugs known as monoclonal antibodies. Opdyta 100mg is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells. Opdyta 100mg is a prescription drug which is used under the supervision of a doctor.

INDICATION

Opdyta 100mg is indicated for the treatment of patients having Melanoma. Opdyta 100mg is indicated for the treatment of patients having Non-Small Cell Lung Cancer. Opdyta 100mg is indicated for the treatment of patients having Kidney (Renal Cell) Cancer.

MECHANISM OF ACTION

Opdyta prohibits the molecule activity called PD-1, and it is a protein which prevents T cells from recognizing and attacking inflamed tissues and cancer cells. PD-1 can deceit the immune system into overlooking melanoma cells as normal cells.

DOSAGE AND ADMINISTRATION

Opdyta recommended dosage for unresectable or metastatic melanoma :
As a single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity

With ipilimumab. The recommended dose of Opdyta is 1mg/kg administrated as an intravenous infusion over 30 minutes, followed by ipilimumab 3mg/kg given as IV over 90 minutes on the same day. Duration 3 weeks of max 4 doses, after completing combination dose continue the single agent treatment.

COMMON SIDE EFFECTS

• Fatigue
• Lymphocytopenia (Low White Blood Cells)
• Low Sodium
• Shortness of breath
• Musculoskeletal Pain
• Decreased Appetite
• Cough

PRECAUTIONS

Immune-mediated pneumonitis may appear to the patients; withhold for moderate and permanently discontinue for serious or life-threatening pneumonitis
Other clinically significant and possible fatal immune-mediated side effects (eg, myocarditis, rhabdomyolysis, myositis, uveitis, iritis, pancreatitis) can appear after therapy discontinuation.

STORAGE

Store at under refrigeration at 2°C to 8°C.

MISSED DOSE

If you missed a dose take it as soon as possible, if time reach for next dose, then skip missed dose and continue regular schedule. Avoid taking two doses at a time. Avoid taking a missed dose within 12hrs of the next dose.

FOR MORE INFORMATION:

EMAIL:
info@blueberrypharma.com

PHONE:
+91-97890 77748

VISIT US:
Labels:

Comments

Post a Comment

Popular posts from this blog

EVEROLIMUS TABLETS COST IN INDIA

EVEROLIMUS DESCRIPTION  Everolimus  belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor).  Everolimus  is an immunosuppressive macrolide. EVEROLIMUS USED FOR Breast cancer  The patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with  Everolimus .  Everolimus  is used in the advanced stage of breast cancer. Neuroendocrine tumors  Everolimus involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer Patient treating with  Everolimus  after the failure of treatment with Sunitinib or Sorafenib.  Everolimus  also used in the condition of Heart, liver, kidney transplantation, Waldenstrom macroglobulinemia, Other carcinoid tumors Brand: Evertor Strength: 10mg Ingredient: Everolimus Company Name: Biocon Tab Count: 10 Tablets MECHANISM OF ACTION Everolimus  is the prohibition o
1 comment
Read more

Everotas 5 mg | Everolimus | Blueberry pharmaceuticals

DESCRIPTION Everotas 5mg belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). Everotas 5mg is an immunosuppressive macrolide. USED FOR Breast cancer  The patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with Everotas. Everotas 5mg is used in an advanced stage of breast cancer. Neuroendocrine tumors  Everotas 5mg involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer  Patient treating with Everotas 5mg after the failure of treatment with Sunitinib or Sorafenib. Everotas 5mg also used in the condition of; Heart, liver, kidney transplantation Waldenström macroglobulinemia Other carcinoid tumors. MECHANISM OF ACTION Everotas is the prohibition of mammalian target of rapamycin (mTOR), a serine-threonine kinase. Everotas bind with intercellular protein (FKBP-12), leads to inhibitory complex formation with
Post a Comment
Read more

Evertor 5 mg | Everolimus | Blueberry pharmaceuticals

EVERTOR 5MG Evertor 5mg belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). Evertor 5mg is an immunosuppressive macrolide. EVERTOR USED FOR Breast cancer  The patient who failed to respond to the tablet letrozole or anastrozole therapy, would be treated with Evertor. Evertor 5mg is used in an advanced stage of breast cancer. Neuroendocrine tumors  Evertor 5mg involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer  patient treating with Evertor 5mg after the failure of treatment with Sunitinib or Sorafenib. Evertor also used in the condition of: Heart, liver, kidney transplantation Waldenstrom macroglobulinemia Other carcinoid tumors MECHANISM OF ACTION Evertor is prohibitor of mammalian target of rapamycin (mTOR), a serine threonine kinase. Evertor bind with intercellular protein (FKBP-12), leads to inhibitory complex formation with mTOR comple
Post a Comment
Read more